Regulation of Tumor Immune Surveillance and Tumor Immune Subversion by TGF-β
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Transforming growth factor-β (TGF-β) is a highly pleiotropic cytokine playing pivotal roles in immune regulation. TGF-β facilitates tumor cell survival and metastasis by targeting multiple cellular components. Focusing on its immunosuppressive functions, TGF-β antagonists have been employed for cancer treatment to enhance tumor immunity. TGF-β antagonists exert anti-tumor effects through #1 activating effector cells such as NK cells and cytotoxic CD8+ T cells (CTLs), #2 inhibiting regulatory/suppressor cell populations, #3 making tumor cells visible to immune cells, #4 inhibiting the production of tumor growth factors. This review focuses on the effect of TGF-β on T cells, which are differentiated into effector T cells or newly identified tumor- supporting T cells.
Abstract
Transforming growth factor-β (TGF-β) is a highly pleiotropic cytokine playing pivotal roles in immune regulation. TGF-β facilitates tumor cell survival and metastasis by targeting multiple cellular components. Focusing on its immunosuppressive functions, TGF-β antagonists have been employed for cancer treatment to enhance tumor immunity. TGF-β antagonists exert anti-tumor effects through #1 activating effector cells such as NK cells and cytotoxic CD8+ T cells (CTLs), #2 inhibiting regulatory/suppressor cell populations, #3 making tumor cells visible to immune cells, #4 inhibiting the production of tumor growth factors. This review focuses on the effect of TGF-β on T cells, which are differentiated into effector T cells or newly identified tumor- supporting T cells.
참고문헌 (33)
- Miyazono K, "Divergence and convergence of TGF-beta", BMP signaling, 2001, pp.187, 265~276
- Li MO, "Transforming growth factor-beta regulation of immune responses", Annu Rev Immunol, 24, pp.99~146 (2006)
- Roberts AB, "The two faces of transforming growth factor beta in carcinogenesis", Proc Natl Acad Sci U S A, 100, pp.8621~8623 (2003)
- Yang YA, "Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects", J Clin Invest, 109, pp.1607~1615 (2002)
- Ge R, "Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo", Clin Cancer Res, 12, pp.4315~4330 (2006)
- Wrzesinski SH, "Transforming growth factor-beta and the immune response: implications for anticancer therapy", Clin Cancer Res, 13, pp.5262~5270 (2007)
- Denoix PF, "Enquete permanent dans les centres anticancereaux", Bull Inst Nat Hyg, 1, pp.70~75 (1946)
- Chen F, "Clinical features of surgical resection for pulmonary metastasis from breast cancer", Eur J Surg Oncol, 35, pp.393~397 (2009)
- Humphrey LJ, "Immunologic responsiveness of the breast cancer patient", Cancer, 46, pp.893~898 (1980)
- Ghiringhelli F, "Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation", J Exp Med, 202, pp.919~929 (2005)
- Alleva DG, "Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2", J Immunol, 153, pp.1674~1686 (1994)
- Bierie B, "Tumour microenvironment: TGFbeta:the molecular Jekyll and Hyde of cancer", Nat Rev Cancer, 6, pp.506~520 (2006)
- Mantovani A, "Cancer-related inflammation", Nature, 454, pp.436~444 (2008)
- Yang L, "Transforming growth factor beta: tumor suppressor or promoter? Are host immune cells the answer?", Cancer Res, 68, pp.9107~9111 (2008)
- Geiser AG, "Transforming growth factor beta 1 (TGF-beta 1) controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatibility antigen expression in the pathogenesis of the TGF-beta 1 null mouse phenotype", Proc Natl Acad Sci U S A, 90, pp.9944~9948 (1993)
- Ljunggren HG, "In search of the missing self: MHC molecules and NK cell recognition", Immunol Today, 11, pp.237~244 (1990)
- Zwirner NW, "Cytokine-driven regulation of NK cell functions in tumor immunity: role of the MICA-NKG2D system", Cytokine Growth Factor Rev, 18, pp.159~170 (2007)
- Lee JC, "Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients", J Immunol, 172, pp.7335~7340 (2004)
- Nam JS, "An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compart ments", Cancer Res, 68, pp.3835~3843 (2008)
- Thomas DA, "TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance", Cancer Cell, 8, pp.369~380 (2005)
- Yamaguchi T, "Regulatory T cells in immune surveillance and treatment of cancer", Semin Cancer Biol, 16, pp.115~123 (2006)
- Kitamura T, "SMAD4-deficient intestinal tumors recruit CCR1＋ myeloid cells that promote invasion", Nat Genet, 39, pp.467~475 (2007)
- Nam JS, "Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17", Cancer Res, 68, pp.3915~3923 (2008)
- Kapp JA, "CD8+ suppressor T cells resurrected", Hum Immunol, 69, pp.715~720 (2008)
- Nakae S, "Antigen-specific T cell sensitization is impaired in IL-17-deficient mice,causing suppression of allergic cellular and humoral responses", Immunity, 17, pp.375~387 (2002)
- Veldhoen M, "TGF beta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells", Immunity, 24, pp.179~189 (2006)
- Miyahara Y, "Generation and regulation of human CD4＋ IL-17- producing T cells in ovarian cancer", Proc Natl Acad Sci U S A, 105, pp.15505~15510 (2008)
- Numasaki M, "Interleukin-17 promotes angiogenesis and tumor growth", Blood, 101, pp.2620~2627 (2003)
- Kryczek I, "Endogenous IL-17 contributes to reduced tumor growth and metastasis", Blood, 114, pp.357~359 (2009)
- Wang L, "IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway", J Exp Med, 206, pp.1457~1464 (2009)
- McGeachy MJ, "The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo", Nat Immunol, 10, pp.314~324 (2009)
- Kortylewski M, "Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment", Cancer Cell, 15, pp.114~123 (2009)
- Martin-Orozco N, "The IL-17", IL-23 axis of inflammation in cancer: friend or foe?, 2009, pp.10, 543~549